Roche CEO on Acquisitions, Innovations, Drug Pricing

The transcript covers Roche's recent acquisitions, including Spark and Sarepta Therapeutics, and their impact on gene therapy advancements. It discusses the challenges posed by biosimilars and Roche's focus on innovation with new therapies in neuroscience. The transcript also highlights Tecentriq's market position, drug pricing transparency, and partnerships with tech companies for personalized healthcare. Finally, it addresses proposed reforms to reduce out-of-pocket expenses in the US healthcare system.

What are the company's views on drug pricing transparency?

How is the company leveraging technology to enhance personalized healthcare?

What reforms does the company propose to reduce out-of-pocket expenses for patients?